ImmunityBio said it secured $100 million in financing transactions, including $75 million of non-dilutive funding under its existing revenue interest purchase agreement with Oberland Capital and a $25 million debt conversion by Nant Capital.
The Oberland transaction lifts total committed capital under the agreement to $375 million, up from $300 million. The company said the amended deal keeps the existing structure in place, with a modest increase in the royalty payback rate and no change to the royalty cap.
At the same time, Nant Capital converted $25 million of principal from the December 2024 promissory note into 4.6 million shares of common stock. That reduced the outstanding debt tied to the $505 million note.
ImmunityBio said the two transactions strengthen its balance sheet as it expands globally after recent approvals. The company now has ANKTIVA approved or authorized in five regulatory jurisdictions covering about 34 countries: the U.S., the U.K., Saudi Arabia, the European Union and Macau.
The Saudi approval in January 2026 also made the kingdom the first jurisdiction to authorize ANKTIVA for lung cancer, alongside its bladder cancer indication. The European Commission followed in February 2026 with conditional marketing authorization across all 27 EU member states plus Iceland, Norway and Liechtenstein, and Macau authorized the treatment in March 2026. The market has reacted to these announcements by moving the company's shares -8.55% to a price of $7.38. If you want to know more, read the company's complete 8-K report here.
